Chemically modified neoantigen-based immunotherapy for targeting KRASG12C-driven tumors

Mai Abdel Mouti; Siim Pauklin

doi:10.1016/j.tips.2023.02.004

Chemically modified neoantigen-based immunotherapy for targeting KRAS^G12C-driven tumors

Trends Pharmacol Sci. 2023 May;44(5):255-257. doi: 10.1016/j.tips.2023.02.004. Epub 2023 Mar 17.

Authors

Mai Abdel Mouti¹, Siim Pauklin²

Affiliations

¹ Botnar Research Centre, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford OX3 7LD, UK.
² Botnar Research Centre, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford OX3 7LD, UK. Electronic address: siim.pauklin@ndorms.ox.ac.uk.

PMID: 36934024
DOI: 10.1016/j.tips.2023.02.004

Abstract

The clinical efficacy and durability of KRAS^G12C-targeted therapies are limited by the development of resistance mechanisms. Here, we provide a review of recent KRAS^G12C-targeted therapy and immunotherapy-unifying strategies that utilize covalently modified peptide/MHC class I complexes as tumor-specific neoantigens to tag drug-resistant cancer cells for destruction with hapten-based immunotherapeutics.

Keywords: KRAS(G12C); immunotherapy; neoantigens; resistance; targeted therapy.

Publication types

Review
Research Support, Non-U.S. Gov't

MeSH terms

Humans
Immunotherapy
Mutation
Neoplasms* / therapy
Proto-Oncogene Proteins p21(ras)*
Treatment Outcome

Substances

Proto-Oncogene Proteins p21(ras)
KRAS protein, human

Grants and funding

25064/CRUK_/Cancer Research UK/United Kingdom